Literature DB >> 6191292

Long-term prevention of vagal atrial arrhythmias by atrial pacing at 90/minute: experience with 6 cases.

P Coumel, P Friocourt, J Mugica, P Attuel, J F Leclercq.   

Abstract

Six patients (5 men, 1 woman) with a history ranging from 3-16 years of resistant vagal atrial arrhythmias were treated by atrial pacing at a rate of 90/Min. These patients have been followed up for an average of 5.5 years (range 2-11 years) with favorable results. The arrhythmias were characterized by daily or weekly attacks of typical atrial flutter and atrial fibrillation occurring mainly or exclusively at night, at rest, or in the digestive periods in otherwise normal hearts of middle-aged patients (first attack between 25 and 54, mean 40). The arrhythmias were resistant to quinidine, and were usually aggravated by digitalis, beta-blockers and verapamil. Amiodarone is usually the only effective drug in this syndrome, but was not used before pacing in the 2 first cases, and was ineffective in the other 4 cases. Electrophysiologic studies confirmed the absence of sick sinus syndrome, and the close relationship between relative bradycardia and the onset of the arrhythmia. Atrial pacing alone totally controlled the arrhythmia in 1 patient; amiodarone was used in conjunction with pacing in 3 patients. In 1 patient the improvement was clear but incomplete, and in 1 patient permanent atrial fibrillation occurred shortly after pacemaker implantation.

Entities:  

Mesh:

Year:  1983        PMID: 6191292     DOI: 10.1111/j.1540-8159.1983.tb05295.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  21 in total

Review 1.  Atrial pacing to prevent atrial fibrillation?

Authors:  S M Sopher; A J Camm
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

Review 2.  New devices and hybrid therapies and new devices for treatment of atrial fibrillation.

Authors:  R B Krol; S Saksena; A Prakash
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

Review 3.  Science, medicine, and the future: Radiofrequency ablation for atrial fibrillation.

Authors:  N R Grubb; S Furniss
Journal:  BMJ       Date:  2001-03-31

Review 4.  Report of the NASPE/NHLBI Round Table on Future Research Directions in Atrial Fibrillation. North American Society of Pacing and Electrophysiology.

Authors:  S Saskena; M J Domanski; E J Benjamin; A J Camm; M D Ezekowitz; B J Gersh; J Jalife; G V Naccarelli; R E Vlietstra; D G Wyse
Journal:  J Interv Card Electrophysiol       Date:  2001-09       Impact factor: 1.900

Review 5.  Endocavitary treatment of atrial fibrillation.

Authors:  S B Olsson; E I Hertervig; O Kongstad; C Meurling; S Yuan
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

6.  Effect of phenylephrine infusion on atrial electrophysiological properties.

Authors:  J W Leitch; M Basta; P J Fletcher
Journal:  Heart       Date:  1997-08       Impact factor: 5.994

Review 7.  Pacing in prevention of atrial fibrillation: the PIPAF studies.

Authors:  F Anselme; N Saoudi; A Cribier
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

8.  Device-based autonomic modulation in arrhythmia patients: the role of vagal nerve stimulation.

Authors:  William A Huang; Kalyanam Shivkumar; Marmar Vaseghi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-05

9.  Interatrial septum pacing: a new approach to prevent recurrent atrial fibrillation.

Authors:  L Padeletti; M C Porciani; A Michelucci; A Colella; P Ticci; S Vena; A Costoli; C Ciapetti; P Pieragnoli; G F Gensini
Journal:  J Interv Card Electrophysiol       Date:  1999-03       Impact factor: 1.900

10.  Design and implementation of the Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) clinical trial. DAPPAF Phase 1 Investigators.

Authors:  S M Fitts; M R Hill; R Mehra; P Friedman; S Hammill; G N Kay; A Prakash; C Webb; S Saksena
Journal:  J Interv Card Electrophysiol       Date:  1998-06       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.